-
艾媒咨询|2021H1中国智能制造专题研究报告
本报告研究涉及企业/品牌/案例:深兰科技,依图科技,远望谷
iiMedia Research(艾媒咨询)数据显示,2020年全国工业软件市场规模达到1974亿元;2020年中国智能硬件市场规模达到10747亿元,同比增长67.1%。随着工业互联网的规模进一步扩大和公有云和信息传输技术的发展,中国制造业智能化将蓬勃发展。其次,智能制造应用场景广阔,赋能汽车、钢铁、3C电子、医疗等行业。 iiMedia Research(艾媒咨询)数据显示,随着技术改革的推动,我国3C电子智能制造业规模2022年将达到5.47万亿元。目前,从生产流程的覆盖率看,我国3C电子智能制造业自动化渗透率仅为20-30%。艾媒咨询分析师认为,智能制造将进一步推动汽车、钢铁、3C电子、医疗等行业数字化、智能化改革,从而释放相关行业的产能。此外,受益于国家政策的大力推动,更多的企业进行研发、生产和投资智能制造装备,形成了智能制造装备产业体系。以数据为基础,智能制造将实现产品设计等全过程的自动化、集成化、信息化,满足产品的个性化、定制化的需求。
As to the data of iiMedia Research, in 2020, the scale of China's industrial software market will reach 1974 billion RMB and the scale of China's intelligent hardware market will reach 1074.7 billion RMB, with a year-on-year growth of 67.1%. With the further expansion of the scale of industrial Internet and the development of public cloud and information transmission technology, China's intelligent manufacturing industry will flourish. Secondly, intelligent manufacturing has broad application scenarios, enabling automobile, steel, 3C electronics, medical and other industries. As to the data of iiMedia Research, with the promotion of technological reform, the scale of 3C electronic intelligent manufacturing industry in China will reach 5.47 trillion RMB in 2022. From the perspective of production process coverage, the penetration rate of 3C electronic intelligent manufacturing automation in China is only 20-30%. The consulting analyst of iiMedia Research believes that intelligent manufacturing will further promote the digital and intelligent reform of automobile, steel, 3C electronics, medical and other industries and release the production capacity of related industries. In addition, benefiting from the strong promotion of national policies, more enterprises carry out R & D, production and investment in intelligent manufacturing equipment, forming an intelligent manufacturing equipment industry system. Based on data, intelligent manufacturing will realize the automation, integration and informatization of the whole process of product design, so as to meet the personalized and customized needs of products. -
艾媒咨询|2021年9月中国医疗健康行业投融资数据分析报告
人口老龄化,人均GDP、人均收入的提升,同时也带来了人们健康需求的增长。近年来,医疗健康产业创新不断涌现,并发展成为最活跃的行业之一,相关细分赛道也维持着较高的增长,收获了资本市场的大量关注。
艾媒咨询通过艾媒数据中心(data.iimedia.cn)查询并发布《2021年9月中国医疗健康行业投融资数据分析简报》,助力投资人与创业者用户即时了解市场趋势,获取关键投资决策所需的数据,把握投资逻辑和最新产业机会。(《艾媒咨询|2021年9月中国医疗健康行业投融资数据分析报告》完整高清PDF版共21页,可点击文章底部报告下载按钮进行报告下载)
The aging of population and the increase of per capita GDP and per capita income have also brought about the growth of people's health demand. In recent years, the innovation of medical and health industry has been emerging and developed into one of the most active industries. The relevant segments have also maintained high growth and gained a lot of attention from the capital market.
Iimedia inquires and publishes the analysis briefing on investment and financing data of “China's medical and health industry in September 2021 through iimedia data center (data. Iimedia. cn), so as to help investors and entrepreneurs understand the market trend in real time, obtain the data required for key investment decisions, and grasp the investment logic and the latest industrial opportunities.(“iiMedia Report |Analysis report on investment and financing data of China's medical and health industry in September 2021”full version has 21 pages in total, please click the Browse HD Report button on the right side of the article to browse the report) -
艾媒咨询|2021全球及中国大健康产业运行大数据及决策分析报告
本报告研究涉及企业/品牌/案例:阿里健康,联合丽格,恒瑞医药,白云山,平安好医生,111集团,新氧,药明巨诺,盘龙药业,先导药业,好大夫在线,优健康,春雨医生,丁香医生,微医
受到人口老龄化、居民患病比例增加等因素影响,国家医疗费用支出不断增加,属于刚性需求;同时,随着人们对健康标准的不断提高以及互联网医疗技术的发展,大健康产业会在相当长的时期内持续保持增长态势。数据显示,2020年中国的大健康产业营收规模超过7万亿元,预计2021年将达8万亿元,增幅达8.1%。其中,得益于大健康产业发展以及疫情期间医药需求增长,生物制药、医疗器械两大细分领域表现良好,成为2020年中国投资热度较高的新经济行业,投资项目金额分别为919亿元和273亿元。
Affected by the aging population and the increasing proportion of residents, the national medical expenditure is increasing, which belongs to the rigid demand; At the same time, with the continuous improvement of people's health standards and the development of internet medical technology, the big health industry will continue to grow for a long time. According to the data, the revenue of China's big health industry will exceed 7 trillion yuan in 2020, and it is expected to reach 8 trillion yuan in 2021, an increase of 8.1%. Among them, thanks to the development of big health industry and the growth of pharmaceutical demand during the epidemic period, biopharmaceuticals and medical devices have performed well, becoming China's new economy industry with high investment enthusiasm in 2020, with investment projects of 91.9 billion yuan and 27.3 billion yuan respectively. -
艾媒咨询|2020年第三季度中国中药材行业数据监测季度报告
本报告研究涉及企业/品牌/案例:同仁堂、香雪制药、白云山。
数据显示,2020年第三季度,中药材价格指数迎来上涨周期。艾媒咨询分析师认为,受动物类等少数品种拉动影响,预计2020年10-11月中药材指数会持续走高,但是在12月维稳。据调查,绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营,采取减少压货炒作等经营方式。因而,预计中药材市场在2020年末旺季会有一波行情的走高,但随着旺季结束,明年年初的价格会重新回落,随着疫情的常态化,中药材市场行情预期会呈周期性波动的态势。
Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation. -
艾媒舆情|2020年315药品食品行业消费者投诉事件盘点
本报告研究涉及企业/品牌/案例:金湖“过期疫苗”事件;聊城医师“开假药” 事件;步长制药“中药注射剂安全”事件;三全水饺涉“非洲猪瘟”事件;网红食品多起事件
顺应消费提质升级要求,重点聚焦产品质量、售后服务、互联网消费等领域侵犯消费者权益的违法违规行为,倡导构建企业自治、行业自律、政府监管和社会监督相结合的消费共同治理机制,推动形成安全放心的消费环境,满足人民对美好生活的需要。
In line with the requirements of improving consumption quality and upgrading, we will focus on violations of consumer rights and interests in product quality, after-sales service, Internet consumption and other fields, advocate the construction of a common consumption governance mechanism that combines enterprise autonomy, industry self-discipline, government supervision and social supervision, promote the formation of a safe and secure consumption environment, and meet the needs of the people for a better life. -
艾媒报告|2020年全球消毒杀毒产品市场分析及发展趋势报告
本报告研究涉及企业/品牌/案例:老肯医疗,新华医疗,威莱,三友化工;
其他提及企业/品牌:滴露,威露士,蓝月亮,洗得宝,威猛先生,如辉,巨光,海氏海诺,威王,净安,优露清,利尔康,安洁,威洁士,欧洁,仁和,泰和科技,京汉股份,比亚迪,仁瑞生物科技,盘龙药业,东北制药等。
2020年4月28日,全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020年全球消毒杀毒产品市场分析及发展趋势报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据,对全球消毒杀毒产品进行全面分析,并且通过对三友化工、威莱集团(威尔士)、新华医疗和老肯医疗的典型企业案例分析,特别结合新冠疫情影响下消毒杀毒用品的用户调研,判断2020-2021年全球消毒杀毒行业发展趋势。随着经济环境和人民生活水平不断改善,国家对于医疗卫生更加重视,卫生投入不断增加,医疗机构数量显著增长,居民的卫生健康意识也持续提高,从需求端拉动消毒产品行业发展。特别在新冠疫情影响下,消毒杀毒产品的需求量骤升,其中小包装的消杀产品需求量特别大,短期消杀用品存在供需结构矛盾。
In 2020, the national medical institutions and other public places need large-scale, long-term, high-frequency disinfection, in addition, the public awareness of home disinfection has also given birth to a huge demand for disinfection products. According to iiMedia Research, the new crown outbreak in 2020 has had an impact on the purchase of disinfection products by 84% of consumers, with the market value of disinfection products expected to reach 38.26 billion yuan for the full year. -
艾媒报告|2020H1后疫时代全球呼吸机等医疗器械产品监测及企业案例报告
本报告研究涉及企业/品牌/案例:美敦力,GE医疗,迈瑞医疗,万孚生物,鱼跃医疗,乐普医疗,九安医疗;其他提及企业/品牌:冠昊生物,华海药业,金域医学,卫宁健康,新和成,健帆生物,费森尤斯医疗,嘉德诺,丹纳赫,史赛克,依视路陆逊梯卡,创业慧康,康恩贝,华北制药,通用电气,西门子,飞利浦,3M,绿盾,霍尼韦尔,保为康POWECOM,CM朝美,UVEX优唯斯,南丁,云南白药,维康WECAN,振德医疗,迪卡侬,锐步,速尔,爱康,KEEP,李宁,亿健,舒华,WALKINGPAD,英派斯,SKG,本博,倍轻松,南极人,凯仕乐,佳仁,茗振,小熊,璐瑶,攀高
2020年4月21日,全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020H1后疫时代全球呼吸机等医疗器械产品监测及企业案例报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据,对全球范围内的医疗器械产品进行全面分析,并且报告聚焦于疫情问题下的呼吸机、额温枪等医疗器械,具体针对美敦力、GE医疗、迈瑞医疗、万孚生物、鱼跃医疗和乐普医疗等典型案例分析,对2020-2021年医疗器械行业发展进行趋势预判。特别在全球新冠肺炎疫情的严峻情势下,呼吸机、额温枪等医疗器械需求猛增,飞利浦、美敦力等西方医疗器械企业快速提高产量,以支持抗疫工作的迫切需求;同时,中国呼吸机等医疗器械企业的海外业务量有明显增长。艾媒咨询分析师认为,全球疫情势必带动医疗器械行业发展,但中国企业应当在保证自身产品质量的基础上抓住机遇,实现业务出海。
According to the data, the global medical device market has continued to increase in size since 2016, and the global medical device market is expected to reach USD 477.4 billion in 2020. Especially under the influence of the New Crown epidemic, the global demand for medical equipment such as ventilators and oxygen concentrators has increased dramatically. Overseas orders for Chinese medical device companies have skyrocketed. Within a certain period, the concept stocks of ventilator in the A-share market have risen. -
艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告
本报告研究涉及企业/品牌/案例:白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业,培力控股,盛实百草,芍花堂,亳药千草,汇群中药
国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research(艾媒咨询)调查显示,有49%的受访用户倾向中医药治疗,与西药基本持平。2018年中国中药材市场规模达1246亿元,同比增长22.40%,在巨大的需求驱动下,中药材种植面积扩大,药材产量将会持续增长。
中药材主要包括上游种植、养殖市场,中游流通市场和下游销售市场三大环节。目前,中药饮片和中成药生产是中药产业的核心,主要包括中药加工,包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面,行业销售收入增速分别在2016和2018年触底回升,华润三九、中国中药、红日药业等上市公司表现良好;中药配方颗粒方面,2006-2016年,中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%,中药配方颗粒或将成为中药饮片加工行业应用广泛的产品;中成药方面,随着国家医改政策的推行,中成药消费需求趋于合理,中成药产量开始回落,但仍处于一个比较高的产量水平,云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。
Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well.
- 1
- 2
- 3
- 4
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告